NovaBridge Biosciences (NBP) Gains from Investment Securities (2019 - 2024)
NovaBridge Biosciences (NBP) posted quarterly Gains from Investment Securities of -$2.0 million for Q3 2024, down 133.47% on a QoQ basis from -$846360.5 in Q4 2020.
NovaBridge Biosciences (NBP) Gains from Investment Securities (2019 - 2024) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Gains from Investment Securities for 3 consecutive years, with -$2.0 million the latest figure, recorded in Q3 2024.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$2.0 million in Q3 2024, while the trailing twelve-month figure through Dec 2024 was -$2.8 million (changed N/A YoY) and the FY2025 annual result came in at $11.6 million, up 183.6% from the prior year.
- Gains from Investment Securities fell to -$2.0 million in Q3 2024 per NBP's latest filing, from -$846360.5 in the prior quarter.
- Over the last five years, Gains from Investment Securities for NBP reached as high as -$846360.5 in Q4 2020 and fell as low as -$2.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | NovaBridge Biosciences | 397.57 Mn | 397.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -1.98 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Dec 31, 2020 | -846,360.50 |
| Dec 31, 2020 | -846,360.50 |
| Dec 31, 2019 | -4,965.83 |
| Dec 31, 2019 | -4,965.83 |
| Sep 30, 2019 | 5.46 Mn |
| Sep 30, 2019 | 5.46 Mn |